Sigyn Therapeutics, Inc. Income Statement
SIGY|5 years of annual SEC 10-K data (FY2014-FY2019)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Sigyn Therapeutics, Inc. reported $143,322 in revenue and $3M in net loss for FY2019. Revenue has grown at a 27.1% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
| Item | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $143.3K | $28.3K | $38.4K | $29.2K | $43.2K |
| Cost of Revenue | $35.7K | $9.7K | $21.4K | $9.9K | $25.3K |
| Gross Profit | $107.7K | $18.6K | $17.0K | $19.3K | $17.9K |
| SG&A Expense | $613.8K | $862.4K | $1.1M | $833.5K | $399.9K |
| Operating Income | -$518.0K | -$1.0M | -$2.0M | -$2.3M | -$387.5K |
| Interest Expense | $55.2K | $352.8K | $790.8K | -$441.2K | - |
| Income Tax | - | $800 | $800 | - | - |
| Net Income | -$3.1M | -$2.6M | -$4.3M | -$2.7M | -$387.5K |
| EPS (Diluted) | -$0.04 | -$0.04 | -$0.09 | -$0.01 | -$0.01 |
| Shares Outstanding | 16.0M | 81.3M | 47.1M | 29.9M | 16.0M |
| Gross Margin | 75.1% | 65.7% | 44.2% | 66.0% | 41.5% |
| Operating Margin | -361.4% | -3544.2% | -5277.4% | -7714.4% | -898.0% |
| Profit Margin | -2145.3% | -9243.2% | -11061.2% | -9224.9% | -898.0% |